David is currently Senior Director of Industry Research and Analysis at BIO in Washington, DC. In this role, he is responsible for financial statistics and analysis of the biotechnology sector and contributes to BIO’s policy activities as well as programming for BIO’s investor conferences. Prior to joining BIO, he was a research scientist at the J. Craig Venter Institute working on the “synthetic cell” team led by Nobel Laureate Hamilton Smith. Before his role in synthetic biology, David worked as a scientist in drug discovery at Amgen, Millennium, and Novartis. His scientific expertise is in protein engineering, enzymology, and synthetic biology. David has earned the Chartered Financial Analyst (CFA) designation and holds a master’s degree in biochemistry.
Technology-based startups are key drivers of America’s economic growth because they make outsized contributions to employment, innovation, and productivity. Unfortunately, policymakers tend to focus indiscriminately on helping small business startups without specifically targeting technology-based startups that have high growth potential. How can policymakers support the formation and success of new technology firms at the national and local level?